e-learning
resources
Stockholm 2002
Wednesday 18.09.2002
Thoracic oncology: diagnosis and prognosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S)
J. Vansteenkiste, C. Dooms, K. Nackaerts, P. De Leyn, B. Anrys, M. Demedts (Leuven, Belgium)
Source:
Annual Congress 2002 - Thoracic oncology: diagnosis and prognosis
Session:
Thoracic oncology: diagnosis and prognosis
Session type:
Oral Presentation
Number:
3728
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Vansteenkiste, C. Dooms, K. Nackaerts, P. De Leyn, B. Anrys, M. Demedts (Leuven, Belgium). Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S). Eur Respir J 2002; 20: Suppl. 38, 3728
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC).
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003
FEV
1
is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results
Year: 2011
A phase I trial of combined carboplatin and topotecan as 2
nd
line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019
The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
The comparison of paclitaxel-carboplatin (PCp) versus gemcitabine-cisplatin (GC) in the treatment of locally advanced or metastatic non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Treatment of unresectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
LATE-BREAKING ABSTRACT: Triplet chemotherapy (paclitaxel/gemcitabine/cisplatin) is more active in advanced squamous cell subtype (SCC) non-small cell lung cancer (NSCLC) than doublet treatment (vinorelbine/cisplatin): A randomized phase III trial in 443 NSCLC patients
Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions
Year: 2012
Treatment of early (stage I/II) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept